Ardent Health Analysts Revise Forecasts Downward Following Disappointing Q3 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Source: Benzinga
Earnings Report: Ardent Health Inc reported a loss of 17 cents per share for Q3, missing the analyst estimate of 41 cents, while sales of $1.577 billion exceeded expectations of $1.547 billion.
Guidance Revision: The company lowered its FY2025 GAAP EPS guidance from a range of $1.73-$2.01 to $0.85-$1.03.
Operational Performance: Despite the earnings miss, Ardent Health saw a 5.8% increase in admissions and a 1.4% rise in total surgeries, with revenue and adjusted EBITDA growing by 9% and 46%, respectively.
Analyst Reactions: Following the earnings announcement, Morgan Stanley downgraded the stock from Overweight to Equal-Weight, reducing the price target from $22 to $12, while Stephens & Co. maintained an Overweight rating but lowered the target from $21 to $17.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 13.73 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 8.250
Low
10.00
Averages
13.73
High
17.00
Current: 8.250
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Face Class Action Lawsuits
- Lawsuit Overview: Varonis Systems, Inc. (NASDAQ:VRNS) faces a class action lawsuit for failing to maintain a high quarterly conversion rate, with investors needing to file a lead plaintiff motion by March 9, 2026, potentially impacting stock price and investor confidence.
- Financial Transparency Issues: Ardent Health, Inc. (NYSE:ARDT) is accused of making misleading statements regarding the collectability of accounts receivable, leading to investor misunderstandings about its financial health, which could affect future financing capabilities.
- Service Capability Concerns: CoreWeave, Inc. (NASDAQ:CRWV) is facing litigation for overstating its ability to meet customer demand, with investors required to act by March 13, 2026, which may result in significant negative impacts on the company's revenue.
- Brand Strategy Missteps: Bath & Body Works, Inc. (NYSE:BBWI) is alleged to have failed to achieve expected growth from its brand collaborations and promotions, with a lead plaintiff motion deadline of March 16, 2026, potentially affecting the company's future financial guidance.
Continue Reading
Ardent Health Faces Class Action Lawsuit
- Class Action Initiation: Purchasers of Ardent Health securities between July 18, 2024, and November 12, 2025, can seek lead plaintiff status by March 9, 2026, alleging violations of the Securities Exchange Act by top executives.
- Financial Misrepresentation Allegations: The lawsuit claims Ardent Health failed to disclose the collectability of accounts receivable accurately, leading to a materially inflated financial position during the class period, which undermines investor confidence.
- Significant Revenue Decline: On November 12, 2025, Ardent Health reported a $43 million drop in Q3 revenue due to adjustments from a new revenue accounting system, causing its stock price to plummet nearly 34%, highlighting concerns over financial transparency.
- Increased Liability Reserves: The company recorded a $54 million increase in professional liability reserves, reflecting social inflationary pressures in medical malpractice claims, which exacerbates investor worries about future profitability.
Continue Reading